Article

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

2023-05-05

Abstract excerpt

<title>Abstract</title> <p>Vaccine protection against COVID-19 wanes over time and has been impacted by the emergence of new variants with increasing escape of neutralization. The COVID-19 Variant Immunologic Landscape (COVAIL) randomized clinical trial (clinicaltrials.gov NCT 05289037) compares the breadth, magnitude and durability of antibody responses induced by a second COVID-19 vaccine boost with mRNA (Moder...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ac8bc1a8-6c85-57ba-a342-3a74030a408a
DOI: 10.21203/rs.3.rs-2653179/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) TrialDOI 10.21203/rs.3.rs-2653179/v1Read

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartographySemantic proximity Read

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity Read

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trialSemantic proximity Read

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.Semantic proximity Read

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccinationSemantic proximity Read

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccineSemantic proximity Read

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostSemantic proximity Read

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartographySemantic proximity Read

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical TrialSemantic proximity Read

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read

A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersSemantic proximity Read

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsSemantic proximity Read